Fraser Wilkes
About Fraser Wilkes
Fraser Wilkes serves as the Associate Director of Vector Process Development at Adaptimmune US, a position he has held since 2019. He holds a Master of Science degree and presented a novel flow cytometry method for rapid assessment of lentiviral detection at the ASGCT Annual Meeting in 2022.
Work at Adaptimmune
Fraser Wilkes serves as the Associate Director of Vector Process Development at Adaptimmune US. He has held this position since 2019, contributing to the company's advancements in vector development for cell therapies. His role involves overseeing processes that enhance the efficiency and effectiveness of vector production, which is critical for the development of innovative treatments.
Education and Expertise
Fraser Wilkes holds a Master of Science degree, which provides him with a strong foundation in scientific principles and methodologies. His educational background supports his expertise in vector process development, particularly in the context of lentiviral vectors used in gene therapy and cell therapy applications.
Background
Fraser Wilkes has been involved in the field of vector development for several years. His experience includes a focus on lentiviral detection methods, which are essential for ensuring the safety and efficacy of gene therapies. His work is characterized by a commitment to advancing methodologies in the biopharmaceutical sector.
Achievements
In 2022, Fraser Wilkes presented a novel flow cytometry method for rapid assessment of lentiviral detection at the ASGCT Annual Meeting. This presentation highlighted his contributions to improving detection techniques, which are vital for the development and quality control of lentiviral vectors in therapeutic applications.